Cutaneous vascular patterns in psoriasis
Giuseppe Micali MD
Dermatology Clinic, University of Catania, Italy
Search for more papers by this authorFrancesco Lacarrubba MD
Dermatology Clinic, University of Catania, Italy
Search for more papers by this authorMaria Letizia Musumeci MD PhD
Dermatology Clinic, University of Catania, Italy
Search for more papers by this authorDoriana Massimino MD
Dermatology Clinic, University of Catania, Italy
Search for more papers by this authorMaria Rita Nasca MD PhD
Dermatology Clinic, University of Catania, Italy
Search for more papers by this authorGiuseppe Micali MD
Dermatology Clinic, University of Catania, Italy
Search for more papers by this authorFrancesco Lacarrubba MD
Dermatology Clinic, University of Catania, Italy
Search for more papers by this authorMaria Letizia Musumeci MD PhD
Dermatology Clinic, University of Catania, Italy
Search for more papers by this authorDoriana Massimino MD
Dermatology Clinic, University of Catania, Italy
Search for more papers by this authorMaria Rita Nasca MD PhD
Dermatology Clinic, University of Catania, Italy
Search for more papers by this authorWe have given specific contributions to the manuscript and do not have any potential conflicts of interest, including specific financial interests, relevant to the subject of the manuscript.
Abstract
Microvascular abnormalities are a characteristic feature of psoriasis and play a crucial role in its pathogenesis. Investigational studies have shown that activated keratinocytes in lesional skin undergo an accelerated epidermal cell turnover and are a major source of pro-angiogenic cytokines, like as VEGF, ESAF, PDECGE/TP, TNF-α, TGF-α and PDGF, suggesting that the epidermis is capable of inducing vascular proliferation. On the other hand, microvascular alterations are essential for the development and persistence of the psoriatic lesions as they provide cellular and tissue nutrition to hyperplastic keratinocytes and promote inflammatory cell migration. Also, dilated and slightly tortuous blood vessels within dermal papillae represent one of the earliest detectable histological changes for all stages of lesional development. Videodermatoscopy is a new non invasive imaging technique able to identify modifications of microvascular architecture in vivo and such evaluation will be useful for the dermatologist both for diagnostic and prognostic evaluation, as well as for post-therapeutic follow-up. In this review, the role of microvascular abnormalities in the pathogenesis of psoriasis as well as the mechanisms underlying vascular changes and their primary therapeutic implications will be reviewed and discussed.
References
- 1 Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol 2007; 25: 524–528.
- 2 Creamer D, Allen MH, Sousa A, et al. Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 1997; 136: 859–865.
- 3 Hern S, Stanton AW, Mellor R, et al. Control of cutaneous blood vessels in psoriatic plaques. J Invest Dermatol 1999; 113: 127–132.
- 4 De Angelis R, Bugatti L, Del Medico P, et al. Videocapillaroscopic findings in the microcirculation of the psoriatic plaque. Dermatology 2002; 204: 236–239.
- 5 Creamer D, Sullivan D, Bicknell R, Barker J. Angiogenesis in psoriasis. Angiogenesis 2002; 5: 231–236.
- 6 Creamer D, Allen M, Jaggar R, et al. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 2002; 138: 791–796.
- 7 Braverman IM. The cutaneous microcirculation. J Investig Dermatol Symp Proc 2000; 5: 3–9.
- 8 Braverman IM, Sibley J. Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol 1982; 78: 12–17.
- 9 Braverman IM. Microcirculation. In: HH Roenigk, HI Maibach (eds). Psoriasis. 3rd edn. Marcel Dekker Inc, New York 1998, 399–407.
- 10 Braverman IM, Yen A. Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 1977; 68: 53–60.
- 11 Wolf JE Jr, Harrison RG. Demonstration and characterization of an epidermal angiogenic factor. J Invest Dermatol 1973; 61: 130–141.
- 12 Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999; 141: 1054–1060.
- 13 Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994; 180: 1141–1146.
- 14 Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003; 102: 161–168.
- 15 Creamer D, Allen MH, Groves RW, Barker JN. Circulating vascular permeability factor/vascular endothelial growth factor in erythroderma. Lancet 1996; 348: 1101.
- 16 Bhushan M, Young HS, Brenchley PE, Griffiths CE. Recent advances in cutaneous angiogenesis. Br J Dermatol 2002; 147: 418–425.
- 17 Hotchkiss KA, Ashton AW, Klein RS, et al. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res 2003; 63: 527–533.
- 18 DeBusk LM, Chen Y, Nishishita T, et al. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 2003; 48: 2461–2471.
- 19 Chen JX, Chen Y, DeBusk L, et al. Dual functional roles of Tie-2/angiopoietin in TNF-alpha-mediated angiogenesis. Am J Physiol Heart Circ Physiol 2004; 287: H187–H195.
- 20 Markham T, Mullan R, Golden-Mason L, et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 2006; 54: 1003–1012.
- 21 Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986; 232: 1250–1253.
- 22 Elder JT, Fisher GJ, Lindquist PB, et al. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 1989; 243: 811–814.
- 23 Bennett SP, Griffiths GD, Schor AM, et al. Growth factors in the treatment of diabetic foot ulcers. Br J Surg 2003; 90: 133–146.
- 24 Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48–50.
- 25 Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 1998; 83: 852–859.
- 26 Kahari VM, Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol 1997; 6: 199–213.
- 27 Cornelius LA, Nehring LC, Roby JD, et al. Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration. J Invest Dermatol 1995; 105: 170–176.
- 28 Bouis D, Kusumanto Y, Meijer C, et al. A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol Res 2006; 53: 89–103.
- 29 Hynes RO, Lively JC, McCarty JH, et al. The diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb Symp Quant Biol 2002; 67: 143–153.
- 30 Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569–571.
- 31 Creamer JD, Barker JN. Vascular proliferation and angiogenic factors in psoriasis. Clin Exp Dermatol 1995; 20: 6–9.
- 32 Senger DR, Ledbetter SR, Claffey KP, et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 1996; 149: 293–305.
- 33 Hern S, Stanton AW, Mellor RH, et al. In vivo quantification of the structural abnormalities in psoriatic microvessels before and after pulsed dye laser treatment. Br J Dermatol 2005; 152: 505–511.
- 34 Kulka JP. Microcirculatory impairment as a factor in inflammatory tissue damage. Ann N Y Acad Sci 1964; 116: 1018–1044.
- 35 Gordon M, Johnson WC, Burgoon CF Jr. Histopathology and histochemistry of psoriasis. II. Dynamics of lesions during treatment. Arch Pathol 1967; 84: 443–450.
- 36 Pinkus H, Mehregan AH. The primary histologic lesion of seborrheic dermatitis and psoriasis. J Invest Dermatol 1966; 46: 109–116.
- 37 Lachapelle JM, Gillman T. Tritiated thymidine labelling of normal human epidermal cell nuclei. A comparison, in the same subjects, of in vivo and in vitro techniques. Br J Dermatol 1969; 81: 603–616.
- 38 Gilje O. Capillary microscopy in the differential diagnosis of skin diseases. Acta Derm Venereol 1953; 33: 303–317.
- 39 Stinco G, Lautieri S, Patrone P. Videocapillaroscopic study in psoriatic patients treated with tacalcitol. G Ital Dermatol Venereol 2006; 141: 227–231.
- 40 Vazquez-Lopez F, Kreusch J, Marghoob AA. Dermoscopic semiology: further insights into vascular features by screening a large spectrum of nontumoral skin lesions. Br J Dermatol 2004; 150: 226–231.
- 41 Micali G, Nardone B, Scuderi A, Lacarrubba F. Videodermatoscopy enhances the diagnostic capability of palmar and/or plantar psoriasis. Am J Clin Dermatol 2008; 9: 119–122.
- 42 Pandya NM, Dhalla NS, Santani DD. Angiogenesis – a new target for future therapy. Vascul Pharmacol 2006; 44: 265–274.
- 43 Horacek J. [Ultrastructural changes of capillaries by UV in psoriatic lesions (author’s transl)]. Z Hautkr 1981; 56: 1218–1223.
- 44 Braverman IM, Sibley J. The response of psoriatic epidermis and microvessels to treatment with topical steroids and oral methotrexate. J Invest Dermatol 1985; 85: 584–586.
- 45 Trevisan G, Magaton Rizzi G, Dal Canton M. Psoriatic microangiopathy modifications induced by PUVA and etretinate therapy. A nail-fold capillary microscopic study. Acta Derm Venereol Suppl (Stockh) 1989; 146: 53–56.
- 46 Strumia R, Altieri E, Romani I, et al. Tacalcitol in psoriasis: a video-microscopy study. Acta Derm Venereol Suppl (Stockh) 1994; 186: 85–87.
- 47 Berardesca E, Vignoli GP, Farinelli N, et al. Non-invasive evaluation of topical calcipotriol versus clobetasol in the treatment of psoriasis. Acta Derm Venereol 1994; 74: 302–304.
- 48 Cordiali-Fei P, Trento E, D’Agosto G, et al. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann N Y Acad Sci 2007; 1110: 578–589.
- 49 Nishimura M, Makino Y, Matugi H. Tacalcitol ointment for psoriasis. Acta Derm Venereol Suppl (Stockh) 1994; 186: 166–168.
- 50 Diaz BV, Lenoir MC, Ladoux A, et al. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem 2000; 275: 642–650.
- 51 Li VW, Li WW. Cyclosporine and angiogenesis in psoriasis. J Am Acad Dermatol 1996; 35: 1019–1021.
- 52 Hernandez GL, Volpert OV, Iniguez MA, et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001; 193: 607–620.
- 53 Braybrooke JP, O’Byrne KJ, Propper DJ, et al. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res 2000; 6: 4697–4704.